COMMUNIQUÉS West-GlobeNewswire
-
Step Pharma secures €2.5 million EIC grant to accelerate development of dencatistat for CTPS2 null gynaecological tumours
19/02/2026 -
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
19/02/2026 -
Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
19/02/2026 -
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
19/02/2026 -
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
19/02/2026 -
Q-Sera announces the first launch of blood collection tubes using its patented Rapclot technology in Japan, opening opportunities for additional global partnerships
19/02/2026 -
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
19/02/2026 -
Ipsen S.A. publie ses comptes consolidés 2025
19/02/2026 -
Philips publishes its Annual Report 2025
19/02/2026 -
Reacta Healthcare Appoints Richard Nagle as Chair of Board of Directors
19/02/2026 -
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
19/02/2026 -
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine
19/02/2026 -
IBA and Shreeji sign multi‑site agreement for four cyclotrons to expand PET radiopharmaceutical manufacturing across India
19/02/2026 -
IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde
19/02/2026 -
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
19/02/2026 -
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026
19/02/2026 -
Zealand Pharma Announces Financial Results for the Full Year 2025
19/02/2026 -
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
19/02/2026 -
Rapid Nutrition PLC – Strategic Outlook and Near-Term Execution Update
19/02/2026
Pages